{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.62","upperLimit":"24.14","value":"20.7"},{"groupId":"OG001","lowerLimit":"16.39","upperLimit":"25.74","value":"20.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"622"},{"groupId":"OG001","value":"308"}],"units":"Participants"}],"description":"Defined as the proportion of participants with PSA concentration \\< 0.02 ng/milliliter (mL).The rate was estimated by the Kaplan-Meier method and reported as percentage of participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Week 25 Day 1 (Day 169)","title":"Undetectable PSA Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}